We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Veeva Systems' (VEEV) Buyout to Bolster Clinical Offering
Read MoreHide Full Article
Veeva Systems Inc. (VEEV - Free Report) recently acquired Veracity Logic — a cloud software provider for randomization and trial supply management (RTSM). Interestingly, the team at Veracity Logic will join Veeva Systems to provide industry-leading software and services that can enable companies to streamline complex processes and accelerate clinical trials.
It is worth mentioning that the solution — offered as Veeva RTSM — offers fast setup timelines and a configurable feature set to cater to a wide range of randomization and supply needs. The solution has supported above 175 trials with sites in 60 countries and covered a variety of trial designs and complexities throughout all therapeutic areas in spaces like pharma/biotech, medical device, and diagnostics.
This buyout is likely to provide a boost to Veeva Systems’ already robust product portfolio.
Rationale of the Buyout
Per management at Veeva Vault R&D and Quality, the buyout can bring RTSM excellence to the company’s customers. Apart from this, the transaction is likely to strengthen Veeva Systems’ clinical offering with flexible and user-friendly RTSM abilities.
Image Source: Zacks Investment Research
From Veracity Logic’s standpoint, this deal will enable it to scale its solution to a bigger market while continuing to provide customer success.
Market Prospects
Per a report by Grand View Research, the global clinical trial supplies market was worth $1.9 billion in 2020 and is projected to witness a CAGR of 6% during the forecast period (2021-2028). Globalization, the growing number of clinical trials, and the number of biologics and biosimilar drugs in clinical trials are some of the major factors likely to drive this market’s growth.
Hence, the transaction comes at an opportune time for Veeva Systems.
Recent Developments
In November, Veeva Systems unveiled two new digital tools at the European Veeva Commercial and Medical Summit Connect event. The company unveiled enhancements in digital tools that add new ways for seamless communication among healthcare professionals (HCPs) and field teams.
In the same month, Veeva Systems' Veeva Vault Quality Suite was adopted by the CBM with the aim of modernizing development and manufacturing services for sponsors.
Price Performance
Shares of the Zacks Rank #3 (Hold) company have lost 2% on a year-to-date basis compared with the industry’s decline of 20.9%.
Stocks to Consider
Some better-ranked stocks in the broader medical space include Thermo Fisher Scientific Inc. (TMO - Free Report) , McKesson Corporation (MCK - Free Report) and NextGen Healthcare, Inc. .
Thermo Fisher’s long-term earnings growth rate is estimated at 14%. The company’s earnings yield of 3.7% compares favorably with the industry’s (3.6%).
McKesson beat earnings estimates in each of the trailing four quarters, the average surprise being 19.9%. The company currently carries a Zacks Rank #2.
McKesson’s long-term earnings growth rate is estimated at 8.9%. The company’s earnings yield of 9.9% compares favorably with the industry’s 3.2%.
NextGen Healthcare surpassed earnings estimates in each of the trailing four quarters, the average surprise being 16%. The company currently carries a Zacks Rank of 2.
NextGen Healthcare’s long-term earnings growth rate is estimated at 8.5%. The company’s earnings yield of 5.9% compares favorably with the industry’s (4.1%).
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Veeva Systems' (VEEV) Buyout to Bolster Clinical Offering
Veeva Systems Inc. (VEEV - Free Report) recently acquired Veracity Logic — a cloud software provider for randomization and trial supply management (RTSM). Interestingly, the team at Veracity Logic will join Veeva Systems to provide industry-leading software and services that can enable companies to streamline complex processes and accelerate clinical trials.
It is worth mentioning that the solution — offered as Veeva RTSM — offers fast setup timelines and a configurable feature set to cater to a wide range of randomization and supply needs. The solution has supported above 175 trials with sites in 60 countries and covered a variety of trial designs and complexities throughout all therapeutic areas in spaces like pharma/biotech, medical device, and diagnostics.
This buyout is likely to provide a boost to Veeva Systems’ already robust product portfolio.
Rationale of the Buyout
Per management at Veeva Vault R&D and Quality, the buyout can bring RTSM excellence to the company’s customers. Apart from this, the transaction is likely to strengthen Veeva Systems’ clinical offering with flexible and user-friendly RTSM abilities.
From Veracity Logic’s standpoint, this deal will enable it to scale its solution to a bigger market while continuing to provide customer success.
Market Prospects
Per a report by Grand View Research, the global clinical trial supplies market was worth $1.9 billion in 2020 and is projected to witness a CAGR of 6% during the forecast period (2021-2028). Globalization, the growing number of clinical trials, and the number of biologics and biosimilar drugs in clinical trials are some of the major factors likely to drive this market’s growth.
Hence, the transaction comes at an opportune time for Veeva Systems.
Recent Developments
In November, Veeva Systems unveiled two new digital tools at the European Veeva Commercial and Medical Summit Connect event. The company unveiled enhancements in digital tools that add new ways for seamless communication among healthcare professionals (HCPs) and field teams.
In the same month, Veeva Systems' Veeva Vault Quality Suite was adopted by the CBM with the aim of modernizing development and manufacturing services for sponsors.
Price Performance
Shares of the Zacks Rank #3 (Hold) company have lost 2% on a year-to-date basis compared with the industry’s decline of 20.9%.
Stocks to Consider
Some better-ranked stocks in the broader medical space include Thermo Fisher Scientific Inc. (TMO - Free Report) , McKesson Corporation (MCK - Free Report) and NextGen Healthcare, Inc. .
Thermo Fisher surpassed earnings estimates in each of the trailing four quarters, the average surprise being 9.02%. The company currently carries a Zacks Rank of 2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Thermo Fisher’s long-term earnings growth rate is estimated at 14%. The company’s earnings yield of 3.7% compares favorably with the industry’s (3.6%).
McKesson beat earnings estimates in each of the trailing four quarters, the average surprise being 19.9%. The company currently carries a Zacks Rank #2.
McKesson’s long-term earnings growth rate is estimated at 8.9%. The company’s earnings yield of 9.9% compares favorably with the industry’s 3.2%.
NextGen Healthcare surpassed earnings estimates in each of the trailing four quarters, the average surprise being 16%. The company currently carries a Zacks Rank of 2.
NextGen Healthcare’s long-term earnings growth rate is estimated at 8.5%. The company’s earnings yield of 5.9% compares favorably with the industry’s (4.1%).